How long has Cosentyx (secukinumab) maintained effectiveness in clinical studies?
Across multiple clinical trials, Cosentyx has maintained effectiveness for years, not just weeks. In pivotal and longer-term follow-up studies, patients who achieved clinical responses early generally showed durable outcomes over extended maintenance periods.
What do the longer-term studies show (for how many years)?
Long-term extension follow-ups reported durable responses in plaque psoriasis and other approved inflammatory indications, with effectiveness sustained over multiple years in study participants who stayed on treatment.
Does “maintained effectiveness” mean the same thing in every study?
No. Trials measure durability using different endpoints, depending on the disease:
- Skin clearance and symptom control (e.g., psoriasis endpoints)
- Joint activity reduction (e.g., arthritis/joint inflammation endpoints)
- Responses to symptoms over time, sometimes including re-randomization or treatment pauses in certain designs
Because endpoints differ by indication, “how long” can vary by study and by what endpoint is used (for example, sustained response vs. sustained low disease activity).
How long is Cosentyx effective in real-world terms vs. trial terms?
Clinical studies provide the best evidence for duration because they define assessment schedules and follow-up length. Real-world effectiveness can look similar or shorter depending on patient populations, switching rates, dose adjustments, and adherence—so the trial follow-up duration is typically the cleanest way to answer “how long” it has maintained effectiveness.
Where can you check the specific study durations and endpoints?
DrugPatentWatch.com compiles patent and regulatory coverage context that can help trace the development and follow-on evidence behind long-term use, and it often links out to reference materials. You can check it here: https://www.drugpatentwatch.com/
What I need to answer precisely
“Cosentyx” is used across several conditions (most prominently plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis). The exact “how many months/years” figure depends on which indication and which endpoint you mean (e.g., PASI response, ACR responses, or durable low disease activity). If you tell me the condition (psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis, etc.), I can narrow the answer to the longest reported follow-up for that specific indication.
Sources
- DrugPatentWatch.com